References
- Al-Hallak MH, Sarfraz MK, Azarmi S, et al. (2011). Pulmonary delivery of inhalable nanoparticles: dry powder inhalers. Ther Deliv 2:1313–24
- Chen X, Huang W, Wong BC, et al. (2012). Liposomes prolong the therapeutic effect of anti-asthmatic medication via pulmonary delivery. Int J Nanomedicine 7:1139–48
- Cocera M, Lopez O, Coderch L, et al. (2000). Alterations in stratum corneum lipid liposomes due to the action of Triton X-100: influence of the level of ceramides on this process. J Control Release 68:387–96
- Dalvi PS, Singh A, Trivedi HR, et al. (2011). Adverse drug reaction profile of oseltamivir in children. J Pharmacol Pharmacother 2:100–3
- Davies BE. (2010). Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J Antimicrob Chemother 65:ii5–10
- Drulis-Kawa Z, Dorotkiewicz-Jach A. (2010). Liposomes as delivery systems for antibiotics. Int J Pharm 387:187–98
- Du B, Li Y, Li X, et al. (2010). Preparation, characterization and in vivo evaluation of 2-methoxystradiol-loaded liposomes. Int J Pharm 384:140–7
- Dutkowski R, Smith JR, Davies BE. (2010). Safety and pharmacokinetics of oseltamivir at standard and high dosages. Int J Antimicrob Agents 35:461–7
- Dutkowski R, Thakrar B, Froehlich E, et al. (2003). Safety and pharmacology of oseltamivir in clinical use. Drug Saf 26:787–91
- Ghosh GC, Nakada N, Yamashita N, Tanaka H. (2010). Oseltamivir carboxylate, the active metabolite of oseltamivir phosphate (Tamiflu), detected in sewage discharge and river water in Japan. Environ Health Perspect 118:103–7
- Glavas-Dodov M, Fredro-Kumbaradzi E, Goracinova K, et al. (2005). The effects of lyophilization on the stability of liposomes containing 5-FU. Int J Pharm 291:79–86
- Gregoriadis G, Perrie Y. (2010). Liposomes. Enc Life Sci. 1–8. DOI: 10.1002/9780470015902.a0002656.pub2
- Gu X, Zhang W, Liu J, et al. (2011). Preparation and characterization of a lovastatin-loaded protein-free nanostructured lipid carrier resembling high-density lipoprotein and evaluation of its targeting to foam cells. AAPS PharmSciTech 12:1200–8
- Gubareva LV, Kaiser L, Hayden FG. (2000). Influenza virus neuraminidase inhibitors. Lancet 355:827–35
- Harrigan PR, Wong KF, Redelmeier TE, et al. (1993). Accumulation of doxorubicin and other lipophilic amines into large unilamellar vesicles in response to transmembrane pH gradients. Biochim Biophys Acta 1149:329–38
- Harush-Frenkel O, Bivas-Benita M, Nassar T, et al. (2010). A safety and tolerability study of differently-charged nanoparticles for local pulmonary drug delivery. Toxicol Appl Pharmacol 246:83–90
- Heinig K, Bucheli F. (2008). Sensitive determination of oseltamivir and oseltamivir carboxylate in plasma, urine, cerebrospinal fluid and brain by liquid chromatography–tandem mass spectrometry. J Chromatogr B 876:129–36
- Huang WH, Yang ZJ, Wu H, et al. (2010). Development of liposomal salbutamol sulfate dry powder inhaler formulation. Biol Pharm Bull 33:512–7
- Li L, Yi T, Lam CW. (2013). Effects of spray-drying and choice of solid carriers on concentrations of Labrasol® and Transcutol® in solid self-microemulsifying drug delivery systems (SMEDDS). Molecules 18:545–60
- Lindemann L, Jacobsen H, Schuhbauer D, et al. (2010). In vitro pharmacological selectivity profile of oseltamivir prodrug (Tamiflu) and active metabolite. Eur J Pharmacol 628:6–10
- Mansour HM, Rhee Y-S, Wu X. (2009). Nanomedicine in pulmonary delivery. Int J Nanomed 4:299–319
- Maxwell SR. (2007). Tamiflu and neuropsychiatric disturbance in adolescents. BMJ 334:1232–3
- Moscona A. (2005). Neuraminidase inhibitors for influenza. N Engl J Med 353:1363–73
- Nicholson KG, Aoki FY, Osterhaus AD, et al. (2000). Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet 355:1845–50
- Panwar P, Pandey B, Lakhera PC, Singh KP. (2010). Preparation, characterization, and in vitro release study of albendazole-encapsulated nanosize liposomes. Int J Nanomed 5:101–8
- Swaminathan J, Enrhardt C. (2012). Liposomal delivery of proteins and peptides. Expert Opin Drug Deliv 9:1489–503